- Home
- NVRO vs CGEN Comparison
NVRO vs CGEN Comparison
Compare NVRO & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NVRO
- CGEN
- Stock Information
- Founded
- NVRO 2006
- CGEN 1993
- Country
- NVRO United States
- CGEN Israel
- Employees
- NVRO N/A
- CGEN N/A
- Industry
- NVRO Medical/Dental Instruments
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NVRO Health Care
- CGEN Health Care
- Exchange
- NVRO Nasdaq
- CGEN Nasdaq
- Market Cap
- NVRO 134.5M
- CGEN 134.3M
- IPO Year
- NVRO 2014
- CGEN 2000
- Fundamental
- Price
- NVRO $3.71
- CGEN $1.65
- Analyst Decision
- NVRO Hold
- CGEN Strong Buy
- Analyst Count
- NVRO 14
- CGEN 1
- Target Price
- NVRO $7.97
- CGEN $4.00
- AVG Volume (30 Days)
- NVRO 395.4K
- CGEN 470.1K
- Earning Date
- NVRO 02-19-2025
- CGEN 11-12-2024
- Dividend Yield
- NVRO N/A
- CGEN N/A
- EPS Growth
- NVRO N/A
- CGEN N/A
- EPS
- NVRO N/A
- CGEN 0.02
- Revenue
- NVRO $419,146,000.00
- CGEN $59,852,000.00
- Revenue This Year
- NVRO N/A
- CGEN $57.27
- Revenue Next Year
- NVRO $0.65
- CGEN N/A
- P/E Ratio
- NVRO N/A
- CGEN $85.40
- Revenue Growth
- NVRO N/A
- CGEN 698.03
- 52 Week Low
- NVRO $3.52
- CGEN $1.35
- 52 Week High
- NVRO $21.66
- CGEN $3.03
- Technical
- Relative Strength Index (RSI)
- NVRO 38.60
- CGEN 56.57
- Support Level
- NVRO $3.60
- CGEN $1.47
- Resistance Level
- NVRO $3.90
- CGEN $1.65
- Average True Range (ATR)
- NVRO 0.29
- CGEN 0.10
- MACD
- NVRO 0.00
- CGEN 0.00
- Stochastic Oscillator
- NVRO 20.88
- CGEN 80.80
About NVRO Nevro Corp.
Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain. Senza generates electrical impulses to relieve pain. The system is implanted by physicians and controlled by patients. It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools, a clinician laptop programmer, a patient remote control, and a mobile charger. The company generates the majority of its revenue in the United States.
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.